• Anoop Kumar Department of Pharmaceutical Sciences and technology, Birla Institute of Technology, Mesra, Ranchi -835215, Jharkhand, India


Efavirenz, Endogenous reverse transcriptase, Apoptosis, Anticancer


Cancer is a potentially fatal disease, where cells abnormally divide which hurts the tissues. The incidences of cancer are increasing worldwide and become one of the leading causes of death. A numbers of anticancer agents are available in the market or under clinical trials used for its treatment, but unfortunately, none of them is able to treat cancer. Thus, the exploration of novel mechanistic pathways of existing molecules may help to develop more effective anticancer agents. Efavirenz, a well-known non-nucleoside reverse transcriptase inhibitor, used in the highly active antiretroviral therapy (HAART) for the treatment of human immunodeficiency virus (HIV) infected patients with tolerable side effects. Newly emerging data revealed that efavirenz has the potential to induce toxic effects against a wide range of cancer cells by altering various cancer pathways. Thus, this existing antiretroviral drug with already known safety profiles could be rapidly utilized for the treatment of various cancers.

Keywords: Efavirenz, Endogenous reverse transcriptase, Apoptosis, Anticancer


Download data is not yet available.


Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M. Causes of cancer in the world: comparative risk assessment of nine behavioral and environmental risk factors. Lancet 2005;366:1784-93.

Boffetta P, Nyberg F. Contribution of environmental factors to cancer risk. Br Med Bull 2003;68:71-94.

Remesh A. Toxicities of anticancer drugs and its management. Int J Basic Clin Pharmacol 2012;1:2-12.

Donaldson KL, Goolsby GL, Wahl AF. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int J Cancer 1994;57:847-55.

Sciamanna I, Landriscina M, Pittoggi C. Inhibition of endogenous reverse transcriptase antagonizes human tumor growth. Oncogene 2005;24:3923-31.

Landriscina M, Spadafora C, Cignarelli M, Barone C. Anti-tumor activity of non-nucleosidic reverse transcriptase inhibitors. Curr Pharm Des 2007;13:737-47.

Bonnet F, Burty C, Lewden C. Changes in cancer mortality among HIV-infected patients: the mortalite 2005 survey. Clin Infect Dis 2009;48:633–9.

Monini P, Sgadari C, Toschi E, Barillari G, Ensoli B. Antitumour effects of antiretroviral therapy. Nat Rev Cancer 2004;4:861-75.

Coutinho RA. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000;92:1823-30.

Dinaker M. Combination antiretroviral therapy (CART) rationale and recommendation. Medicine 2011;507-10.

Hecht M, Erber S, Harrer T. Efavirenz has the highest antiproliferative effect of non-nucleoside reverse transcriptase inhibitors against pancreatic cancer cells. PloS One 2015;10:e0130277. Doi:10.1371/journal.pone.0130277. [Article in Press]

Patnala R, Lee SH, Dahlstrom JE. Inhibition of LINE-1 retrotransposon-encoded reverse transcriptase modulates the expression of cell differentiation genes in breast cancer cells. Breast cancer research and treatment 2014;143:239-53.

Hecht M, Harrer T, Buttner M. Cytotoxic effect of efavirenz is selective against cancer cells and associated with the cannabinoid system. AIDS 2013;27:2031–40.

Sinibaldi-Vallebona P, Lavia P, Garaci E, Spadafora C. A role for endogenous reverse transcriptase in tumorigenesis and as a target in differentiating cancer therapy. Genes Chromosomes Cancer 2006;45:1–10.

Kumar A, Sasmal D, Sharma N, Bhaskar A, Chandra S, Mukhopadhyay K, et al. Deltamethrin, a pyrethroid insecticide, could be a promising candidate as an anticancer agent. Med Hypotheses 2015;85:145-7.



How to Cite

Kumar, A. “EFAVIRENZ, A WELL KNOWN ANTIVIRAL DRUG, MIGHT BE A NEW OPTION IN THE TREATMENT OF CANCER”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 8, no. 7, July 2016, pp. 6-7, https://journals.innovareacademics.in/index.php/ijpps/article/view/12203.



Letter to Editor